'Prostate cancer drug Docetaxel extended my life'

Early treatment with a chemotherapy drug extends the lives of patients with advanced prostate cancer by nearly two years, a major study has shown.

Docetaxel is normally given after hormone treatment has failed.

The findings come from the largest ever prostate cancer trial undertaken involving 6,500 men.

Michele Paduano reports.